Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Sieren, Jessica C

University Of Iowa
United States

Lung cancer screening efficacy enhanced through radiomic and epigenetic biomarkers 5R01CA267820-03 Nicholas Hodges, Ph.D.
Sigel, Keith Magnus

Icahn School Of Medicine At Mount Sinai
United States

The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors 4R01CA256660-05 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Simeone, Diane M

University Of California, San Diego
United States

Biomarker Validation in Pancreatic Cystic Neoplasms 5U01CA282272-03 Matthew Young, Ph.D.
Siminski, Suzanne M.

Frontier Sci & Technology Rsch Fdn, Inc
United States

CASCADE Coordinating Center 5U24CA275417-04 Maria Silvina Frech, Ph.D., M.S.
Singal, Amit

Ut Southwestern Medical Center
United States

Clinical Validation Center for Hepatocellular Carcinoma 5U01CA271887-04 Indu Kohaar, Ph.D., M.Phil., M.Sc.
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules 4U01CA283935-03 Sidney Fu, M.D.
Singal, Amit

Ut Southwestern Medical Center
United States

Clinical Validation Center for Hepatocellular Carcinoma 5U01CA271887-04 Indu Kohaar, Ph.D., M.Phil., M.Sc.
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis 5R01CA222900-06
Singal, Amit

Ut Southwestern Medical Center
United States

Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States 5U01CA230694-05
Siskind, Leah J

University Of Louisville
United States

Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease 1R01CA305985-01 Marjorie Perloff, M.D.
Siskind, Leah J

University Of Louisville
United States

Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease 1R01CA305985-01 Marjorie Perloff, M.D.
Skates, Steven J

Massachusetts General Hospital
United States

Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls 5U01CA260758-05 Claire Zhu, Ph.D.
Skates, Steven J

Massachusetts General Hospital
United States

Genome-wide methylation and proteomic analysis of uterine lavage and cervical swab for early detection of ovarian cancer 5U2CCA271871-03 Christos Patriotis, Ph.D., M.Sc.
Skubitz, Amy Patrice

University Of Minnesota
United States

A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection 5R01CA262153-05 Christos Patriotis, Ph.D., M.Sc.
Slager, Susan L

Mayo Clinic Rochester
United States

The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL) 4R01CA258465-04 Nicholas Hodges, Ph.D.